Pharma wins permanent price shield on orphan drugs under Medicare
S. 1862 — ORPHAN Cures Act · Filed by John Barrasso (R-WY) · 1 cosponsor · Introduced May 22, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill expands the orphan drug exemption from Medicare's drug price negotiation program. It allows drugs that were once designated as orphan drugs (for rare diseases) to retain their exemption even after they are approved for broader uses, and it clarifies that orphan drugs treating multiple rare diseases qualify for the exemption. The primary beneficiaries are pharmaceutical manufacturers of orphan drugs, who gain protection from price negotiation on these medications.
Why we flagged it
The bill's operative mechanism is to expand and clarify exemptions from Medicare's drug price negotiation authority, shielding a class of drugs from price controls. This is a direct carve-out for pharmaceutical manufacturers, not a public health measure.
What the text implies
- Drugs approved for rare diseases can now retain orphan exemption indefinitely even after gaining approval for common conditions, potentially allowing manufacturers to avoid price negotiation on blockbuster drugs that originated as orphan designations.
- The expansion to 'one or more rare diseases' (plural) may capture drugs treating multiple rare indications simultaneously, broadening the exemption beyond the original intent of protecting single-indication orphan drugs.
The full analysis lists 3 implications of this text.
Who stands to gain
pharmaceutical manufacturers with orphan drug portfolios; biotech companies developing rare disease treatments